SRR33346948
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.350
- KRAS_SIGNALING_DN+0.210
- OXIDATIVE_PHOSPHORYLATION+0.130
- ESTROGEN_RESPONSE_LATE+0.060
- SPERMATOGENESIS+0.050
- APICAL_SURFACE+0.030
- BILE_ACID_METABOLISM-0.010
- COAGULATION-0.010
- FATTY_ACID_METABOLISM-0.020
- TGF_BETA_SIGNALING-0.020
Top 10 suppressed
- MYC_TARGETS_V2-0.570
- UNFOLDED_PROTEIN_RESPONSE-0.470
- E2F_TARGETS-0.460
- G2M_CHECKPOINT-0.420
- MTORC1_SIGNALING-0.400
- DNA_REPAIR-0.380
- ALLOGRAFT_REJECTION-0.360
- IL6_JAK_STAT3_SIGNALING-0.350
- TNFA_SIGNALING_VIA_NFKB-0.340
- PI3K_AKT_MTOR_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A245-01A-22R-A16F-07 | — | B | 0.898 |
| 2 | SRR1516063 | — | — | 0.896 |
| 3 | SRR1324431 | GTEX | — | 0.895 |
| 4 | MNG540 | — | — | 0.893 |
| 5 | SRR1471435 | GTEX | — | 0.886 |
| 6 | SRR1357021 | GTEX | — | 0.885 |
| 7 | TCGA-CF-A47X-01A-31R-A23W-07 | — | — | 0.884 |
| 8 | SRR1409282 | GTEX | — | 0.883 |
| 9 | SRR1311285 | GTEX | — | 0.882 |
| 10 | SRR1403831 | GTEX | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |